PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 0.39 ▲ 0.01 (1.69%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Onconova Therapeutics Inc | ONTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.0284 | -6.96% | 0.3796 | 0.42 | 0.3759 | 0.4169 | 0.408 | 19:59:20 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.3855 | 0.386 | 0.0005 | 0.13% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 15,479 | 14,718,759 | $ 0.399039 | $ 5,873,359 | 23,836,054 | 0.1027 - 5.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:20 | formt | 1,000 | $ 0.386 | USD |
Onconova Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 52.66M | 138.73M | $ -20.57M | -7.93 | - | 137.22M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Onconova Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/23/2020 | 08:39 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/23/2020 | 08:30 | GlobeNewswire Inc. | Onconova Therapeutics Regains Rigosertib Rights in Greater.. |
| 1/17/2020 | 17:26 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/13/2020 | 16:07 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 1/10/2020 | 16:04 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 1/03/2020 | 17:30 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/03/2020 | 13:27 | GlobeNewswire Inc. | Onconova Therapeutics, Inc. Announces Closing of $10 Million.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.416 | 0.445 | 0.3247 | 0.4119442 | 17,785,872 | -0.0364 | -8.75% |
| 1 Month | 0.33 | 0.69 | 0.3158 | 0.4377769 | 27,273,438 | 0.0496 | 15.03% |
| 3 Months | 0.53 | 0.77 | 0.1027 | 0.3520074 | 18,812,870 | -0.1504 | -28.38% |
| 6 Months | 2.35 | 2.84 | 0.1027 | 0.3693372 | 8,510,200 | -1.97 | -83.85% |
| 1 Year | 1.96 | 5.25 | 0.1027 | 0.3958628 | 4,426,911 | -1.58 | -80.63% |
| 3 Years | 38.40 | 58.20 | 0.1027 | 2.68 | 1,858,089 | -38.02 | -99.01% |
| 5 Years | 52.95 | 122.55 | 0.1027 | 4.19 | 1,181,188 | -52.57 | -99.28% |
Onconova Therapeutics Description
| Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways. |
